news
Biopharma sees strong Q2 2023 market cap growth
Johnson & Johnson have been shifted from the top position in the market capitalisation ranking for the first time, due to Eli Lilly having the largest growth during Q2 2023, research shows.
List view / Grid view
Eli Lilly
news
New CKD treatment option approved in EU
The first SGLT2 inhibitor to demonstrate a statistically significant reduction in all-cause hospitalisations in chronic kidney disease (CKD) patients versus placebo has been approved in the EU.
news
Alzheimer’s therapeutics market to reach $6.8 billion by 2032
A large patient population and limited treatment options are expected to expand the Alzheimer’s therapeutics market at a CAGR of 9.3 percent, suggested a report.
news
Top biopharma firms report Q3 market capitalisation decline
The top 20 biopharma companies averaged a market capitalisation decline of $3.45 trillion in Q2 to $3.14 trillion in Q3 2022, says GlobalData.
news
MCAP for top bio/pharma companies reached $3.4 trillion in 2021
Market capitalisation (MCAP) for the top bio/pharma companies grew 24.9 percent in 2021, with BioNTech and Moderna entering the top 20 for the first time.
news
Tirzepatide maintains AC1 and weight control in type 2 diabetes patients
The highest dose of tirzepatide led to an A1C reduction of 2.58 percent and reduced body weight by 11.7kg in Phase III study.
news
Jardiance® displays 21 percent risk reduction in heart failure patients
Jardiance displayed a 21 percent risk reduction in adults with heart failure with preserved ejection fraction in Phase III study.
news
New NICE draft guidance recommends abemaciclib for breast cancer
NICE has published draft guidance recommending Eli Lilly's twice-daily pill abemaciclib for advanced HER2-negative breast cancer.
article
Biologics: a leadership journey
Behind every technological advance there is often a leadership story just as interesting. In this article, Ben Woollard highlights key leadership behaviours that have been fundamental in biological innovation and suggests how businesses can implement these attributes to strive forward in a new era of biologics.
article
COVID-19: the big repurpose and even bigger pharmaceutical partnership
Heidi West discusses how academia, government and the pharmaceutical industry can work together to potentially repurpose drugs for the treatment of COVID-19.
news
Pharma programmes for employees to volunteer in fight against COVID-19
Lilly, Merck and Pfizer have announced how they will enable their employees to volunteer in programmes to combat COVID-19 while on base pay.
news
FDA hands Boehringer and Lilly complete response letter for insulin adjunct
Boehringer Ingelheim and Eli Lilly have received a complete response letter from the US FDA for their sNDA of empagliflozin 2.5mg, an insulin adjunct.
news
Insight into 2020’s clinical trials landscape
Oncology, industry-sponsored and a combination of the two, will account for the majority of clinical trials categories over the course of the coming year.
news
FDA grants priority review to selpercatinib New Drug Application
Priority review has been given to the NDA for selpercatinib to treat advanced RET fusion-positive non-small cell lung cancer, RET-mutant medullary thyroid cancer and RET fusion-positive thyroid cancer.
news
Eli Lilly to acquire biopharma company Dermira for $1.1bn
According to Eli Lilly, the company will acquire Dermira in an all-cash transaction for $1.1 billion, at a rate of $18.75 per share.
